| Analysis | Metabolite Name | Measured Value | Units | Gender:female | Glycemic status:diabetic | Neuropathy |
|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 1759509 | Peak area normalized | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 1843412 | Peak area normalized | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 2105333 | Peak area normalized | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 2166137 | Peak area normalized | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 2663969 | Peak area normalized | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 2835154 | Peak area normalized | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3213327 | Peak area normalized | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3264361 | Peak area normalized | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3292590 | Peak area normalized | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3344586 | Peak area normalized | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3407324 | Peak area normalized | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3799366 | Peak area normalized | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3905035 | Peak area normalized | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 4225698 | Peak area normalized | no neuropathy |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|